The National Medical Products Administration approved the codeine phosphate of Shanghai Shyndec Pharmaceutical's (SHA:600420) unit, Sinopharm Group Industrial, into China's listing of chemical raw materials, according to a Shanghai Stock Exchange filing on Friday.
The drug can be used to treat severe and frequent dry coughs, the pharmaceutical company said.
The company invested 4.6 million yuan into the research and development of the drug, the filing said.
The company's shares rose more than 1% in recent trade.